Hope for Preventing Stomach Cancer: Enhanced Antibiotic Shows Promise Against H. Pylori
A slight chemical modification has dramatically increased the effectiveness of the antibiotic metronidazole, making it 60 times stronger against the stomach bacterium Helicobacter pylori. Researchers at the Technical University of Munich (TUM) announced this breakthrough on March 18, 2026, potentially paving the way for more effective prevention and treatment of stomach cancer.
The Threat of H. Pylori Infection
Approximately 43 percent of the world’s population is infected with Helicobacter pylori, an anaerobic bacterium that thrives in the absence of air.1 This bacterium can cause chronic inflammation of the stomach lining (gastritis), leading to stomach ulcers and significantly increasing the risk of stomach cancer.1
Challenges with Current Treatments
Standard therapies for H. Pylori infection typically involve a three-drug combination, including metronidazole, amoxicillin, and clarithromycin, alongside a stomach acid inhibitor.1 Yet, H. Pylori is increasingly developing resistance to metronidazole, necessitating higher doses and combinations with additional antibiotics.1
How the New Drug Candidate Works
Researchers at TUM, led by Prof. Stephan A. Sieber, Chair of Organic Chemistry II at the TUM School of Natural Sciences, investigated the mechanisms of action of metronidazole. They discovered that, in addition to inducing oxidative stress in the bacterium—causing chemical reactions that damage cellular components—metronidazole also targets two key protective proteins in H. Pylori.1 These proteins are an enzyme responsible for detoxifying harmful reactive oxygen species and a protein that repairs damaged proteins.
Building on these findings, the team developed chemically modified variants of metronidazole, known as ether derivatives.2 These modifications allow the drug to bind more effectively and stably to the target proteins, hindering the bacterium’s ability to defend against oxidative stress.2
Promising Results from Laboratory and Animal Studies
Laboratory tests demonstrated that the new drug candidate was up to 60 times more effective against H. Pylori, including antibiotic-resistant strains.2 Importantly, the modified drug did not exhibit increased toxicity to human cells.2 In mouse studies, the drug completely eradicated H. Pylori infection, even at low doses, with less disruption to the gut microbiome compared to standard therapies.2
Next Steps and Future Outlook
“We have developed a very promising potential active ingredient to reduce the risk of stomach cancer,” said Prof. Sieber.1 However, the results must be confirmed in clinical studies on humans. If successful, this could represent a significant medical breakthrough in the fight against stomach cancer.
The discovery builds upon the foundational work of researchers John Warren and Barry Marshall, who were awarded the 2005 Nobel Prize in Medicine for demonstrating that H. Pylori is a major cause of gastritis and stomach ulcers.1
Keep reading